Journal of Cancer Diagnosis
Open Access

Anal cancer; Diagnosis; Human papillomavirus; Imaging modalities; Biopsy; Screening; Molecular diagnostics; Artificial intelligence; Multidisciplinary approach

Introduction

Anal cancer is a relatively rare form of cancer that develops in the tissues of the anus. Despite its rarity; its diagnosis can be challenging due to the stigma surrounding the area and the often vague or overlooked symptoms [1]. However; advancements in medical technology and increased awareness have improved detection rates and treatment outcomes. In this article; we will delve into the various aspects of anal cancer diagnosis, including symptoms, screening methods, diagnostic tests, and treatment options.

Anal cancer, although relatively rare compared to other malignancies, represents a significant health concern due to its increasing incidence rates and associated morbidity and mortality [2]. The majority of anal cancers are of squamous cell carcinoma (SCC) histology, arising from the epithelial lining of the anal canal. Other histological types, such as adenocarcinoma, melanoma, and lymphoma, are less common but still encountered in clinical practice [3]. The incidence of anal cancer has been rising steadily over the past few decades, particularly among certain high-risk populations, including men who have sex with men (MSM), individuals with human immunodeficiency virus (HIV) infection, and those with a history of anogenital HPV infection [4]. HPV infection, notably HPV-16 and HPV-18, has been identified as a major risk factor for the development of anal squamous cell carcinoma, emphasizing the importance of preventive measures such as HPV vaccination. Despite advances in cancer screening and diagnosis, anal cancer remains a diagnostic challenge, often presenting with nonspecific symptoms that may mimic benign conditions such as hemorrhoids or anal fissures [5]. Moreover, the lack of routine screening programs for anal cancer, unlike other malignancies such as colorectal cancer, contributes to delays in diagnosis and treatment initiation.

The diagnosis of anal cancer typically involves a combination of clinical evaluation, imaging studies, and histopathological analysis. Clinical evaluation may include a thorough medical history, physical examination, and digital rectal examination (DRE), supplemented by imaging modalities such as endoanal ultrasound (EAUS), magnetic resonance imaging (MRI), or computed tomography (CT) scans to assess tumor extent and local invasion [6]. Definitive diagnosis often requires tissue biopsy, either through endoscopic or surgical approaches, followed by histopathological examination to confirm the presence of malignancy and determine histological subtype. In recent years, there have been significant advancements in the diagnosis of anal cancer, driven by improvements in imaging technology, molecular diagnostics, and biomarker identification [7]. Novel techniques such as optical coherence tomography (OCT), confocal laser endomicroscopy (CLE), and positron emission tomography (PET) have shown promise in enhancing the accuracy of tumor detection and characterization. Furthermore, the development of molecular and genetic markers may aid in risk stratification, prognosis prediction, and targeted therapy selection for patients with anal cancer [8].

Despite these advancements, several challenges remain in the diagnosis of anal cancer, including the need for standardized diagnostic criteria, improved accessibility to diagnostic services, and the development of noninvasive screening tests for high-risk populations [9]. Additionally, addressing disparities in anal cancer diagnosis and treatment among underserved communities is crucial for reducing healthcare inequalities and improving patient outcomes. Early detection and accurate diagnosis are paramount in the management of anal cancer, enabling timely initiation of appropriate treatment and improving patient survival rates. Continued research efforts aimed at refining existing diagnostic strategies, identifying novel biomarkers, and expanding access to screening programs are essential for addressing the growing burden of anal cancer and improving overall patient care [10].

Symptoms of anal cancer

Anal cancer symptoms can vary widely and may resemble those of other less serious conditions, leading to delayed diagnosis. Some common symptoms include:

• Persistent anal itching
• Pain or pressure in the anal area
• Bleeding from the anus or rectum
• Changes in bowel habits, such as diarrhea or constipation
• Unexplained weight loss
• Feeling a lump or mass near the anus
• Changes in the size or shape of stools
• Pain during bowel movements

It is essential to consult a healthcare professional if you experience any of these symptoms, especially if they persist or worsen over time.

Diagnosis of anal cancer

Diagnosing anal cancer typically involves a series of steps aimed at confirming the presence of cancerous cells and determining the extent of the disease. These steps may include:

A healthcare provider may perform a visual inspection of the anus and surrounding area to look for any abnormalities or signs of cancer.

During a DRE, a gloved, lubricated finger is inserted into the rectum to feel for any lumps or abnormalities in the tissues.

If suspicious lesions are detected during the physical examination or DRE, a biopsy may be performed. During a biopsy, a small sample of tissue is removed from the affected area and examined under a microscope to check for cancer cells.

Imaging tests such as MRI, CT scan, PET scan, or ultrasound may be used to determine the size and location of the tumor and whether the cancer has spread to other parts of the body.

Similar to a Pap smear for cervical cancer screening, an anal Pap smear involves collecting cells from the anus to check for abnormalities that may indicate the presence of pre-cancerous or cancerous changes.

A colonoscopy may be recommended to examine the entire colon and rectum for any abnormalities or signs of cancer.

Screening for anal cancer

Routine screening for anal cancer is not yet widely recommended for the general population, unlike screenings for other types of cancer such as breast, cervical, or colorectal cancer. However, certain groups of individuals may be at higher risk for anal cancer and may benefit from screening, including:

• Men who have sex with men (MSM)
• Individuals with a history of anal HPV infection or genital warts
• HIV-positive individuals
• Individuals with a history of anal dysplasia or previous anal cancer
• Screening methods for anal cancer may include anal Pap smears, high-resolution anoscopy (HRA), or a combination of both.

Treatment options

Treatment for anal cancer depends on several factors, including the stage of the cancer, the patient's overall health, and personal preferences. Common treatment options may include:

Surgery: Surgery may be recommended to remove the cancerous tissue. This may involve removing the tumor alone (local excision) or removing a larger portion of the anus or rectum (resection).

Radiation therapy: Radiation therapy uses high-energy rays to kill cancer cells and shrink tumors. It may be used alone or in combination with surgery.

Chemotherapy: Chemotherapy involves the use of drugs to kill cancer cells. It may be used alone or in combination with radiation therapy (chemoradiation).

Targeted therapy: Targeted therapy drugs target specific molecules or pathways involved in cancer growth and spread. They may be used in combination with other treatments or as part of clinical trials.

Immunotherapy: Immunotherapy works by stimulating the body's immune system to recognize and attack cancer cells. It may be used in advanced or recurrent anal cancer.

Palliative care: Palliative care focuses on relieving symptoms and improving the quality of life for patients with advanced or incurable cancer. It may include pain management, symptom control, and emotional support.

It is essential for patients to discuss their treatment options thoroughly with their healthcare team to make informed decisions that align with their goals and preferences.

Conclusion

Diagnosing anal cancer can be challenging due to the subtlety of symptoms and the lack of routine screening for the general population. However, early detection and prompt treatment can significantly improve outcomes for patients with anal cancer. Increased awareness, improved screening methods, and advancements in treatment options offer hope for better outcomes and quality of life for individuals affected by this rare but potentially serious disease. Regular check-ups, maintaining a healthy lifestyle, and seeking medical attention for any concerning symptoms are essential steps in detecting and managing anal cancer effectively.

References

1. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, et al. (2006) Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 367: 489-98.

Indexed at, Google Scholar, Crossref

2. Kyrgiou M, Athanasiou A, Kalliala IE, Paraskevaidi M, Mitra A, et al. (2017) Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. The Cochrane Database of Systematic Reviews 11: 12847.

Indexed at, Google Scholar, Crossref

3. Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, et al. (2013) 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital Tract Disease 17: 1-27.

Indexed at, Google Scholar, Crossref

4. Rapp L, Chen JJ (1998) the papillomavirus E6 proteins. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1378: 1-19.

Indexed at, Google Scholar, Crossref

5. Monnier-Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, et al. (2006) Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. Journal of Clinical Virology. 35: 270-7.

Indexed at, Google Scholar, Crossref

6. Lowy DR, Schiller JT (2006) Prophylactic human papillomavirus vaccines. The Journal of Clinical Investigation 116: 1167-73.

Indexed at, Google Scholar, Crossref

7. Gajjar K, Martin-Hirsch PP, Bryant A, Owens GL (2016) Pain relief for women with cervical intraepithelial neoplasia undergoing colposcopy treatment. The Cochrane Database of Systematic Reviews 7: 6120.

Indexed at, Google Scholar, Crossref

8. Nagi CS, Schlosshauer PW (2006) Endocervical glandular involvement is associated with high-grade SIL. Gynecologic Oncology 102 (2): 240-3.

Indexed at, Google Scholar, Crossref

9. Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP (1998) Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstetrics and Gynecology 92: 727-35.

Indexed at, Google Scholar, Crossref

10. Solomon D, Davey D, Kurman R, Moriarty A, Prey M, et al. (2002) The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287 (16): 2114-9.

Indexed at, Google Scholar, Crossref